Ampersand Biomedicines
Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.
$65M Series B+ ·
Source: fundraisingfox.com
Funding history ↓Signals
Ampersand Biomedicines | 946 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
- Series B+ · $65MSource: fundraisingfox.com
- X account created
- Website created
Founders and team
AK
NA
Noubar Afeyan FounderRA
Raffi Afeyan FounderJG
Jason Gardner CEO & Director
Acquisitions
| Acquired company | Price | Announced |
|---|---|---|
| Not disclosed publicly | Date not given |
Investors
Companies like Ampersand Biomedicines
NNewLimit$435M Series B+ · Jun 2026
AAugustine Therapeutics$85M Series A · Mar 2025
OOctant BioSeries B+ · Oct 2025
FFive Alarm BioSeed · Feb 2023MMatchpoint Therapeutics$150M Series B+ · Oct 2026
SStorm Therapeutics$56M Series B+ · Apr 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/ampersand-biomedicines (get a free API key).